The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Daratumumab approved for use in England and Wales
On 17 January 2018, it was announced that daratumumab will now be available in the form of a monotherapy on the NHS, for the treatment of patients with Multiple Myeloma (MM) in England and Wales. This approval was granted by the National Institute of Clinical Excellence (NICE) and follows the decision granted by the Scottish Medicines Consortium (SMC) in October – see previous MM Hub article.
The therapy has been made available through the Cancer Drugs Fund (CDF), which provides faster access to the most promising cancer treatments, and will now allow access to MM patients that have received three prior lines of therapy that included a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) and have experienced disease progression during their last therapy. Access to such a novel therapy that has shown far-reaching benefits will be extremely welcome news for MM patients in England and Wales, although the limited indication as only a fourth line treatment is not quite what was hoped for and patient groups will certainly campaign for its extended use.
References